Increase in CD4+CD25+/total CD4+ ratio among tumor-bearing individuals was associated with tumor advancement and suggestive of a more suppressive functionality in the immune systems of this group of tumor-bearing mice treated with the protein. This evidence concerns the gene CD4 and neoplasm.